## 3 Results
### Enrichment Analysis  
Enrichment analysis showed that these eGenes were significantly enriched in 12 pathways for visceral adipose tissue, 18 pathways for the liver, 22 pathways for skeletal muscle, and 20 pathways for the pancreas (\(P_{\rm BH}\) \(<\) 0.05; Supplementary Tables S1-S4). None of these enriched pathways were identified when analyzing the mapped genes physically close to T2 DM GWAS signals (Supplementary Table S5). Except for major histocompatibility complex (MHC)-related pathways, only two pathways were found to be enriched: 'lyosome' for the pancreas and 'other glycan degradation' for skeletal muscle. Subsequent enrichment analysis was performed to investigate whether the eGenes shared by multiple tissues were enriched in these two pathways (Tables 1 and 2). In particular, the eGenes shared by the the pancreas and skeletal muscle showed the largest enrichment in the term 'lysosome' (\(P_{\rm BH}\) = 1.1 \(\times\) 10\({}^{-3}\)).  
\begin{table}
\begin{tabular}{c c c c c} \hline \hline \multirow{2}{*}{**Tissue a**} & \multicolumn{2}{c}{**eGenes Relevant to Lysosome**} & \multicolumn{2}{c}{\(p\)**-Value c**} \\ \cline{2-5}  & \multicolumn{2}{c}{**Name**} & **No b** & **Raw** & **Adjusted d** \\ \hline A & GGA3, NPC1, IDUA, HYAL3, CTSH, & 8 & \(\mathbf{2.9\times 10^{-2}}\) & \(3.2\times 10^{-1}\) \\  & CTSW, APS52, AP3B2 & & & \\ \hline L & CTSH, AP3S2, ABCB9 & 3 & \(1.0\times 10^{-1}\) & \(4.3\times 10^{-1}\) \\ \hline M & NTC1, IDUA, CTSZ, HYAL3, GBA, & & & \\  & CTSH, ACP2, AP3S2, DNASE2, & & & \\  & ABCB9, AP3B2 & & & \\ \hline P & NPC1, IDUA, HYAL3, GBA, CTSH, & & & \\  & AP3S2, ABCB9, AP3B2 & & & \\ \hline AL & CTSH, AP3S2 & 2 & \(1.7\times 10^{-1}\) & \(4.1\times 10^{-1}\) \\ \hline AM & NPC1, IDUA, HYAL3, CTSH, AP3S2, & 6 & \(1.7\times 10^{-2}\) & \(1.2\times 10^{-1}\) \\  & AP3B2 & & & \\ \hline AP & NPC1, IDUA, HYAL3, CTSH, AP3S2, & 6 & \(\mathbf{2.9\times 10^{-3}}\) & \(\mathbf{1.8\times 10^{-2}}\) \\ \hline LM & CTSH, AP3S2, ABCB9 & 3 & \(\mathbf{3.0\times 10^{-2}}\) & \(8.9\times 10^{-2}\) \\ \hline LP & CTSH, AP3S2, ABCB9 & 3 & \(\mathbf{3.5\times 10^{-2}}\) & \(1.1\times 10^{-1}\) \\ \hline MP & NPC1, IDUA, HYAL3, GBA, CTSH, & & & \\  & AP3S2, ABCB9, AP3B2 & & & \\ \hline ALM & CTSH, AP3S2 & 2 & \(1.2\times 10^{-1}\) & \(2.5\times 10^{-1}\) \\ \hline ALP & CTSH, AP3S2 & 2 & \(1.2\times 10^{-1}\) & \(2.7\times 10^{-1}\) \\ \hline AMP & NPC1, IDUA, HYAL3, CTSH, AP3S2, & 6 & \(\mathbf{8.5\times 10^{-4}}\) & \(\mathbf{4.7\times 10^{-3}}\) \\ \hline LMP & CTSH, AP3S2, ABCB9 & 3 & \(\mathbf{1.9\times 10^{-2}}\) & \(5.1\times 10^{-2}\) \\ \hline ALMP & CTSH, AP3S2 & 2 & \(9.9\times 10^{-2}\) & \(2.0\times 10^{-1}\) \\ \hline \hline \end{tabular} a Two or more letters indicate that enrichment was analyzed using eGenes shared by tissues. A: visceral adipose tissue; L: liver; M: skeletal muscle; P: pancreas. b There was a total of 128 lysosome-related genes in the KEGG pathway. c Significance with \(p\) \(<\) 0.05 is presented in bold. d Adjusted \(p\)-values were obtained using the Benjamini-Hochberg method to correct for multiple testing.  
\end{table}
Table 2: Enrichment of ‘other glycan degradation’-related eGenes resulted from T2 DM GWAS signals.  
\begin{table}
\begin{tabular}{c c c c c} \hline \hline \multirow{2}{*}{**Tissue a**} & \multicolumn{2}{c}{**eGenes Relevant to Other Glycan**} & \multicolumn{2}{c}{\(p\)**-Value c**} \\ \cline{2-5}  & \multicolumn{2}{c}{**Degradation**} & & & \\ \cline{2-5}  & \multicolumn{2}{c}{**Name**} & **No b** & **Raw** & **Adjusted d** \\ \hline A & MAN2C1, GBA2 & 2 & \(9.1\times 10^{-2}\) & \(8.0\times 10^{-1}\) \\ \hline L & MAN2C1 & \(1\) & \(1.5\times 10^{-1}\) & \(5.7\times 10^{-1}\) \\ \hline \hline \end{tabular}
\end{table}
Table 1: Enrichment of ‘lysosome’-related eGenes resulted from T2 DM GWAS signals.